Search Page

1

Cite

Share

Molecular markers of the risk of oral cancer.

Lippman SM, Hong WK. Lippman SM, et al. N Engl J Med. 2001 Apr 26;344(17):1323-6. doi: 10.1056/NEJM200104263441710. N Engl J Med. 2001. PMID: 11320393 No abstract available.

Cite

Share

2

Cite

Share

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Thompson IM, et al. Among authors: lippman sm. N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918. N Engl J Med. 2004. PMID: 15163773 Clinical Trial.

Cite

Share

3

Cite

Share

Molecular signatures of lung cancer--toward personalized therapy.

Herbst RS, Lippman SM. Herbst RS, et al. Among authors: lippman sm. N Engl J Med. 2007 Jan 4;356(1):76-8. doi: 10.1056/NEJMe068218. N Engl J Med. 2007. PMID: 17202459 No abstract available.

Cite

Share

4

Cite

Share

Molecular based treatment of oral cancer.

Sudbø J, Bryne M, Mao L, Lotan R, Reith A, Kildal W, Davidson B, Søland TM, Lippman SM. Sudbø J, et al. Among authors: lippman sm. Oral Oncol. 2003 Dec;39(8):749-58. doi: 10.1016/s1368-8375(03)00098-8. Oral Oncol. 2003. PMID: 13679198 Retracted. Review.

Cite

Share

5

Cite

Share

The influence of resection and aneuploidy on mortality in oral leukoplakia.

Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A. Sudbø J, et al. Among authors: lippman sm. N Engl J Med. 2004 Apr 1;350(14):1405-13. doi: 10.1056/NEJMoa033374. N Engl J Med. 2004. PMID: 15070790 Retracted.

Cite

Share

6

Cite

Share

Head and neck cancer.

Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Vokes EE, et al. Among authors: lippman sm. N Engl J Med. 1993 Jan 21;328(3):184-94. doi: 10.1056/NEJM199301213280306. N Engl J Med. 1993. PMID: 8417385 Review. No abstract available.

Cite

Share

7

Cite

Share

Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.

Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Lippman SM, et al. N Engl J Med. 1993 Jan 7;328(1):15-20. doi: 10.1056/NEJM199301073280103. N Engl J Med. 1993. PMID: 8416267 Clinical Trial.

Cite

Share

8

Cite

Share

Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.

Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. Lotan R, et al. Among authors: lippman sm. N Engl J Med. 1995 May 25;332(21):1405-10. doi: 10.1056/NEJM199505253322103. N Engl J Med. 1995. PMID: 7723796

Cite

Share

9

Cite

Share

Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions.

Yang H, Lippman SM, Huang M, Jack Lee J, Wang W, Spitz MR, Wu X. Yang H, et al. Among authors: lippman sm. Eur J Cancer. 2008 Jul;44(11):1603-11. doi: 10.1016/j.ejca.2008.05.006. Epub 2008 Jun 23. Eur J Cancer. 2008. PMID: 18579371 Free PMC article.

Cite

Share

10

Cite

Share

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. Thompson IM, et al. Among authors: lippman sm. N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24. N Engl J Med. 2003. PMID: 12824459 Clinical Trial.

Cite

Share